These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32566235)

  • 21. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
    Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
    Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
    Van Gaal L; Souhami E; Zhou T; Aronson R
    J Clin Transl Endocrinol; 2014 Jun; 1(2):31-37. PubMed ID: 29159080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study.
    Chawla M; Panneerselvam D; Gundgurthy A; Sud S; Alamchandani R; Aneja P; Nair R; Korukonda KR
    Cureus; 2024 May; 16(5):e60815. PubMed ID: 38910691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan.
    Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Sep; 7(3):299-307. PubMed ID: 30603277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
    Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
    BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
    Blüher M; Kurz I; Dannenmaier S; Dworak M
    World J Diabetes; 2012 Sep; 3(9):161-9. PubMed ID: 23125906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
    Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
    Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
    Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
    Gross JL; Rogers J; Polhamus D; Gillespie W; Friedrich C; Gong Y; Monz BU; Patel S; Staab A; Retlich S
    BMJ Open; 2013 Mar; 3(3):. PubMed ID: 23468467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.
    Tatosian DA; Guo Y; Schaeffer AK; Gaibu N; Popa S; Stoch A; Langdon RB; Kauh EA
    Diabetes Ther; 2013 Dec; 4(2):431-42. PubMed ID: 24163113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPP-4 inhibitors: pharmacological differences and their clinical implications.
    Ceriello A; Sportiello L; Rafaniello C; Rossi F
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S57-68. PubMed ID: 25171159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.